Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
- Details
- Category: Novo Nordisk
Novo Nordisk has announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza® (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events.
Pfizer commences $5 billion accelerated share repurchase
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) has entered into an accelerated share repurchase agreement with Goldman, Sachs & Co. (GS&Co.) to repurchase $5 billion of Pfizer's common stock. This agreement is part of Pfizer's existing share repurchase authorization.
AstraZeneca's potential medicine for neuromyelitis optica receives FDA Orphan Drug Designation
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the investigational anti-CD19 monoclonal antibody, MEDI-551, for the treatment of patients with neuromyelitis optica (NMO) as well as neuromyelitis optica spectrum disorders (NMOSD).
Sanofi Pasteur and MSD announce intent to end joint vaccines operations in Europe
- Details
- Category: Sanofi
Sanofi Pasteur and MSD, known as Merck in the United States and Canada, today announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.
GSK names winners of 2015 Discovery Fast Track Challenge
- Details
- Category: GlaxoSmithKline
GSK has announced the winners of its third Discovery Fast Track Challenge. The programme is sponsored by GSK's Discovery Partnerships with Academia (DPAc) group to provide an opportunity for academic researchers in Europe and North America to collaborate with GSK and explore novel ideas for potential medicines.
Bristol-Myers Squibb and LabCentral team up in Cambridge, Massachusetts to support promising biotech startup companies
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, today announced an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor.
Merck, Pfizer and Verastem announce combination trial of avelumab and VS-6063 in ovarian cancer
- Details
- Category: Pfizer
Merck, Pfizer and Verastem have entered into an agreement to evaluate avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063**, an investigational focal adhesion kinase (FAK) inhibitor, in patients with advanced ovarian cancer.
More Pharma News ...
- Merck and the European Molecular Biology Laboratory announce drug discovery collaboration
- AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine
- Acalabrutinib recommended for orphan drug designation in Europe for three indications
- Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment
- Johnson & Johnson issues call for innovative ideas to reduce HIV infections in Sub-Saharan Africa
- Four inspiring innovations which help reduce child deaths in developing countries share $1 million prize from GSK and Save the Children
- Novartis shareholders approve all resolutions proposed by Board of Directors